Timing of empagliflozin in heart attack angioplasty
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether giving empagliflozin (a diabetes drug also used for heart failure) before, during, or after an emergency angioplasty for a first heart attack can improve recovery. It is for South Asian patients who are having a first heart attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are of South Asian origin (Pakistani, Indian, Bangladeshi, Sri Lankan, or Nepali).
- This is your first heart attack, and you are arriving at the hospital within 12 hours of symptoms.
- Your doctor plans to do emergency angioplasty with stenting.
- Your kidney function is adequate (not severely reduced).
- You have not had prior heart attacks, stents, or bypass surgery.
- You are not taking a similar class of diabetes drugs (SGLT2 inhibitors) in the last 3 months.
- You are able to swallow oral medication (or crushed tablets with water).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This trial tests whether dapagliflozin (a diabetes medicine also used for heart protection) can reduce harmful heart “remodeling” after an acute heart attack. It may help your heart function and structure recover over the following 6 months.
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.